Rezolute Inc. has published a document detailing preliminary patient demographics and baseline characteristics from the Phase 3 sunRIZE study of Ersodetug for hypoglycemia due to congenital hyperinsulinism. The document outlines the trial's progress, including the randomized, double-blind design, treatment arms, and interim analysis results. The study focuses on assessing the efficacy of Ersodetug in treating this rare pediatric condition. The full document can be accessed through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.